NHS National Generic Pharmaceuticals Wave 13

The NHS Commissioning Board (operating under the name of NHS England) · Awarded

Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Status
Awarded
Country
United Kingdom
Region
England
Sector
Manufacturing
Reference
FaT-ocds-h6vhtk-02be28
Published
2022-01-14

Tender summary

Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months)

This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.

Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.

Register for full access

IT tenders · Construction tenders · Sitemap